Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, Missouri 65212, USA.
Am J Physiol Renal Physiol. 2010 Mar;298(3):F655-61. doi: 10.1152/ajprenal.00373.2009. Epub 2009 Dec 9.
Renin-angiotensin system (RAS) activation contributes to kidney injury through oxidative stress. Renin is the rate-limiting step in angiotensin (ANG II) generation. Recent work suggests renin inhibition improves proteinuria comparable to ANG type 1 receptor (AT1R) blockade (ARB). Thereby, we investigated the relative impact of treatment with a renin inhibitor vs. an ARB on renal oxidative stress and associated glomerular structural and functional changes in the transgenic Ren2 rat, which manifests hypertension, albuminuria, and increased tissue RAS activity. Young Ren2 and age-matched Sprague-Dawley (SD) controls (age 6-9 wk) were treated with a renin inhibitor (aliskiren), an ARB (irbesartan), or vehicle for 21 days. Ren2 rats exhibited increases in systolic pressure (SBP), albuminuria, and renal 3-nitrotyrosine content as well as ultrastructural podocyte foot-process effacement and diminution of the podocyte-specific protein nephrin. Structural and functional alterations were accompanied by increased renal cortical ANG II, AT1R, as well as NADPH oxidase subunit (Nox2) expression compared with SD controls. Abnormalities were attenuated to a similar extent with both aliskiren and irbesartan treatment. Despite the fact the dose of irbesartan used caused a greater reduction in SBP than aliskerin treatment (P < 0.05), the effects on proteinuria, nephrin, and oxidative stress were similar between the two treatments. Our results highlight both the importance of pressor-related reductions on podocyte integrity and albuminuria as well as RAS-mediated oxidant stress largely comparable between ARB and renin inhibition treatment.
肾素-血管紧张素系统(RAS)的激活通过氧化应激导致肾脏损伤。肾素是血管紧张素(ANG II)生成的限速步骤。最近的研究表明,肾素抑制可改善蛋白尿,与血管紧张素 1 型受体(AT1R)阻断剂(ARB)相当。因此,我们研究了肾素抑制剂与 ARB 治疗对转基因 Ren2 大鼠肾脏氧化应激及相关肾小球结构和功能变化的相对影响,该大鼠表现为高血压、白蛋白尿和组织 RAS 活性增加。年轻的 Ren2 和年龄匹配的 Sprague-Dawley(SD)对照(6-9 周龄)用肾素抑制剂(阿利克仑)、ARB(厄贝沙坦)或载体治疗 21 天。Ren2 大鼠的收缩压(SBP)、白蛋白尿和肾脏 3-硝基酪氨酸含量增加,以及足细胞突起融合和足细胞特异性蛋白nephrin 减少。与 SD 对照组相比,结构和功能改变伴随着肾皮质 ANG II、AT1R 以及 NADPH 氧化酶亚基(Nox2)表达增加。阿利克仑和厄贝沙坦治疗均可使这些异常减轻到相似程度。尽管厄贝沙坦的剂量导致 SBP 降低幅度大于阿利克仑(P < 0.05),但两种治疗方法对蛋白尿、nephrin 和氧化应激的影响相似。我们的结果强调了降压相关的足细胞完整性和白蛋白尿的重要性,以及 ARB 和肾素抑制治疗中 RAS 介导的氧化应激之间的相似性。